Loading
Life sciences · Journal article
Advances in Cancer Biology - Metastasis · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/objective Hepatocellular carcinoma is the third leading cause of cancer-related mortality worldwide. Sorafenib's utility is limited by adverse effects and resistance development, processes mediated through the AKT/NF-κB and apoptotic pathways. This study evaluated the orlistat– Spirulina combination as a novel approach targeting these pathways and compared its effects with sorafenib. Methods HCC was induced in mice using a DEN/CCl4 initiator-promoter protocol. Evaluations included histopathology; liver function tests (AST, ALT); Western blotting for AKT, p-AKT, NF-κB p65, and p53; RT-PCR for Pten, Bax, Bcl2, Il10, Il6, Il1b, and Tnfa; TUNEL assay for apoptosis; and micro-PET imaging for tumor metabolic activity. Results Combination treatment significantly improved liver histopathology, liver index, tumor multiplicity, tumor area, and reduced serum liver enzymes. It reduced p-AKT via Pten upregulation, enhanced apoptosis through increased p53 and Bax with decreased Bcl2, and reduced inflammation via NF-κB p65 downregulation and decreased Il6, Il1β, and Tnfα. While the combination therapy showed no therapeutic difference with sorafenib, it demonstrated superior anti-inflammatory activity through a greater reduction in Tnfα and Il6. Micro-PET imaging confirmed reduced tumor metabolic activity, with no difference from sorafenib. Conclusion The orlistat– Spirulina combination exerts anticancer effects in the DEN/CCl4-induced HCC model, a similar effect to sorafenib, through modulating the AKT/NF-κB axis and p53/Bax/Bcl2-mediated apoptosis. Additionally, it demonstrates superior anti-inflammatory activity. These findings support further preclinical investigation of this combination as a potential therapeutic strategy for HCC.